Medical Research Council

What Medical Research Council does

The Medical Research Council (MRC), founded in 1913 and headquartered in Swindon, UK, is the UK's principal public funder of medical research and a constituent council of UK Research and Innovation (UKRI). MRC funds world-leading discovery and translational research across UK universities, NHS trusts, and research institutes to accelerate diagnosis, advance treatment, and prevent human illness, with a £602 million core budget for 2025-26 allocated by the UK government through UKRI. Its portfolio spans clinical trials (e.g., BESS for bronchiolitis, PROTECT for cardiac gene therapy, MAST for microbiome therapeutics), major research centres (CoRE CTI for clinical trial innovation, Centers of Research Excellence in cardiac gene therapy), and flagship initiatives including the UK Cancer Vaccine AI & Supercomputing Project using sovereign AI systems (Dawn, ISAMBARD-AI) and the CIARA AI scientist platform. MRC's business model is non-commercial: it distributes competitive grants via the UKRI funding finder and regional partnership networks rather than selling products or services, and it operates as a non-departmental public body with no private shareholders, pricing model, or revenue diversification beyond government allocation. Its customers are UK-based clinical and academic researchers across multiple disciplines, including cancer research, mental health (via the GLAD study multi-omics dataset targeting 12,000 participants), gene therapy, and microbiome science, with strategic partnerships extending to NIHR, British Heart Foundation, Wellcome Trust, Innovate UK, and commercial entities such as Chiesi Farmaceutici and Johnson & Johnson.

Name

Medical Research Council

Legal name

Medical Research Council (MRC)

Website

https://mrc.ac.uk

Company type

Private

Founded year

1913

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

The Medical Research Council (MRC), founded in 1913 and headquartered in Swindon, UK, is the UK's principal public funder of medical research, operating under UKRI with a £602 million 2025-26 budget. It distributes competitive grants to universities, NHS trusts, and research institutes across discovery and translational science, including clinical trials, gene therapy, AI-powered cancer vaccines, and mental health research.

Ownership category

akta.pro rank

Product category

Medical Research Funding

NAICS

Scientific Research and Development Services (5417), Voluntary Health Organizations (813212)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industries

Research & Science Grantmaking Foundations (BPAGAKAI), Investigator & Site Training / GCP Support (HLAGACAF)

Keywords

• Medical research funding
• Translational research grants
• Clinical trial innovation
• Biomedical discovery research
• Health research council

Headquarters

HQ city

Swindon

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. Government funding allocation: MRC receives core budget allocation from UK Research and Innovation, which is part of the UK government's science funding framework. MRC core budget was £602 million in 2025-26.
2. Government budget allocation (South Africa): South African government allocated R410m to the Medical Research Council as part of healthcare funding.

Distribution channels3 records

Marketing channels5 records

Core offering

The Medical Research Council (MRC) is the UK's principal public funder of medical research, operating as a non-departmental public body within UK Research and Innovation (UKRI). It distributes competitive grant funding to universities, NHS trusts, and research institutes to support world-leading discovery and translational research aimed at accelerating diagnosis, advancing treatment, and preventing human illness. It also delivers targeted funding programmes including the Regional Accounts for Clinical Researchers (RACRs), the £50 million Mental Health Goals programme, the MRC CoRE CTI for clinical trial innovation, and the UK Cancer Vaccine AI & Supercomputing Project.

Product overview

Medical Research Council (MRC) is the UK's major public funder of medical research, operating as part of UK Research and Innovation. MRC provides competitive grant funding to support research across universities, NHS trusts, and research institutes rather than manufacturing products. The core offering is research funding programmes supporting discovery and translational research. Major initiatives include the Regional Accounts for Clinical Researchers (RACRs) pilot programme providing protected research time and mentoring; the UK Cancer Vaccine AI & Supercomputing Project using AI supercomputers and CIARA platform for personalized cancer vaccines; the £50 million Mental Health Goals programme creating multi-omics datasets and industry partnerships; and the MRC CoRE CTI clinical trials innovation centre developing new trial methodologies. MRC also funds specific clinical trials including BESS (bronchiolitis surfactant research), PROTECT (cardiac gene therapy), and MAST (microbiome therapeutics).

Differentiator

Problem solved

Functional benefit

Products and services

• Regional Accounts for Clinical Researchers (RACRs) Pilot Programme A £10 million four-year pilot funding programme providing protected research time, mentoring, and skills development for clinical researchers at critical career transition points, delivered through ten regional accounts across the UK. Targets clinical researchers in NHS and academic institutions facing retention challenges.
• UK Cancer Vaccine AI & Supercomputing Project AI-powered research initiative developing personalized cancer vaccines using sovereign AI supercomputers (Dawn and ISAMBARD-AI) and the CIARA AI scientist platform to analyze tumor biology and coordinate vaccine development across a consortium of over 2,500 scientists, clinicians, technologists, and patients.
• Mental Health Goals Programme £50 million programme funded by the Office for Life Sciences to transform mental health research infrastructure, including development of the world's largest nationally representative multi-omics dataset for severe depression (12,000 additional GLAD study participants) and an Industry Alliance Team for streamlined academic-industry partnerships.
• MRC CoRE CTI (Centre of Research Excellence in Clinical Trial Innovation) £50 million Centre of Research Excellence in Clinical Trial Innovation partnered with NIHR, developing pioneering approaches to clinical trial design and delivery including Multi-Arm Multi-Stage (MAMS) and personalized trial designs. Aims to reduce the 20-year timeline for bringing new treatments from laboratory to clinical practice and collaborates with over 60 organisations worldwide.
• Human Disease Modelling Initiative £15.9 million initiative co-funded by MRC, Wellcome Trust, and Innovate UK for next-generation human disease modelling using advanced human-based in vitro models of disease for improved drug discovery and reduced reliance on animal models, involving several UK universities.

Quantifiable outcome

• Aiming to reduce current 20-year timeline for bringing new treatments from laboratory to clinical practice
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and flagship.

• Imperial College LondoncoreStrategic or Co-development Partner · 19 June 2026Imperial College London is a research institute partner in the £10M Regional Accounts for Clinical Researchers (RACRs) pilot programme, providing protected research time, mentoring, and skills development for clinical researchers in south-west London region.
• Brunel University LondoncoreStrategic or Co-development Partner · 19 June 2026Brunel University London participates as a research institute partner in the RACRs pilot programme, collaborating with other universities and NHS trusts in south-west London to address clinical academic career retention challenges.
• CIARA (AI Scientist Platform)coreTechnology or Integration · 3 June 2026CIARA serves as the AI scientist platform in the UK Cancer Vaccine AI & Supercomputing Project, analyzing tumor biology and coordinating vaccine development for the consortium of over 2,500 scientists.
• Imperial College LondoncoreStrategic or Co-development Partner · 10 March 2026Imperial College London sponsors the MAST Phase 2a trial evaluating EBX-102-02, funded by the Medical Research Council. The trial assesses whether a single pre-emptive oral dose can preserve gut microbiome diversity during stem cell transplantation.
• King's College LondoncoreStrategic or Co-development Partner · 6 February 2026King's College London researchers co-lead workstreams in the £50 million Mental Health Goals programme, including developing the world's largest multi-omics dataset for severe depression and creating an Industry Alliance Team.
• University of OxfordcoreStrategic or Co-development Partner · 6 February 2026Oxford University researchers co-lead workstreams in the Mental Health Goals programme, contributing to mental health research infrastructure transformation in partnership with MRC.
• Cardiff UniversitycoreStrategic or Co-development Partner · 6 February 2026Cardiff University researchers co-lead workstreams in the Mental Health Goals programme alongside King's College London and Oxford University.
• Golden Jubilee University National HospitalcoreStrategic or Co-development Partner · 6 February 2026Scotland's Golden Jubilee University National Hospital conducted the first patient worldwide to receive gene therapy during a heart bypass operation as part of the PROTECT trial, supported by MRC and British Heart Foundation.
• Cell and Gene Therapy CatapultcoreStrategic or Co-development Partner · 6 February 2026Cell and Gene Therapy Catapult provides infrastructure support for the PROTECT trial (gene therapy during heart bypass), working with MRC and British Heart Foundation.
• National Institute for Health and Care Research (NIHR)flagshipStrategic or Co-development Partner · 9 January 2026NIHR partners with MRC on the £50m Centre of Research Excellence in Clinical Trial Innovation to develop pioneering approaches to clinical trial design and delivery, aiming to reduce the 20-year timeline for bringing treatments to clinical practice.
• Johnson & JohnsoncoreStrategic or Co-development Partner · 9 December 2025Johnson & Johnson provides a bispecific antibody for the RISE research programme focused on reducing cytokine release syndrome in cancer immunotherapy, with Poolbeg Pharma's POLB 001 TOPICAL trial included in the programme.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Howard Hughes Medical Institute (HHMI):
• National Institutes of Health (NIH): US federal agency and the world's largest public biomedical research funder. Comparable as a government-backed medical research funding body with discovery-to-translational scope, though considerably larger and with different governance and political dynamics.
• European Research Council (ERC): EU body funding frontier research across disciplines including life sciences. Comparable as a public grantmaking body supporting investigator-led research with peer-review processes and translational scope.
• Bill & Melinda Gates Foundation: Largest philanthropic funder of global health research, including vaccine development and translational programmes. Comparable as a non-government research funder with similar mission of accelerating treatments, though focused on global health priorities.
• National Science Foundation (NSF): US federal agency funding fundamental science research across disciplines. Comparable as a government-backed scientific research funder with broad portfolio, though MRC is more concentrated on medical research.

Direct peers

• Wellcome Trust: Major UK and global charitable foundation funding health and biomedical research. Most directly comparable peer given shared UK footprint, overlapping disease areas, co-funding of MRC initiatives (e.g., the £15.9M human disease modelling programme), and grantmaking model.
• National Institute for Health and Care Research (NIHR): UK government funder of clinical and applied health research, flagship partner with MRC on the £50M CoRE CTI. Directly comparable in mission (clinical research funding), geography (UK), and patient population served.
• Cancer Research UK (CRUK): UK-based charity funding cancer research across discovery, translation, and clinical trials. Comparable as a UK grantmaking body for medical research, particularly relevant given MRC's expanding role in personalized cancer vaccine development.
• British Heart Foundation (BHF): UK charity funding cardiovascular research and co-funder with MRC of cardiac gene therapy Centers of Research Excellence (~US$128M over 14 years). Comparable disease-focused funder with strong translational and clinical trial activity.

Regional players

• Innovate UK: Sister UKRI body focused on business-led innovation, including the £15.9M human disease modelling initiative co-funded with MRC. Directly comparable as a UK research funding body operating under the same UKRI umbrella.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/c/medicalresearchcouncil
• LinkedInlinkedin.com/company/8541
• Xx.com/The_MRC
• Facebookfacebook.com/MRCComms

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medical Research Council